Loading clinical trials...
Loading clinical trials...
The objective of this study is to evaluate the safety and effectiveness of OC-02 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Oyster Point Pharma, Inc.
NCT07463950 · Dry Eye Disease (DED)
NCT07363824 · Dry Eye Disease, Iron
NCT07396441 · Juvenile Open Angle Glaucoma, Dry Eye Disease (DED), and more
NCT05865379 · Dry Eye Disease
NCT05865457 · Dry Eye Disease
Louisville
Louisville, Kentucky
Andover
Andover, Massachusetts
Nashville
Nashville, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions